Clinical Trial Update: Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP) [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating daily AKR-501 tablets for 28 days in patients with chronic immune thrombocytopenia; the study has completed and results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• AKR-501

Snippet

Sponsor: Eisai Inc. | Conditions: Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic | Phase 2 | Status: COMPLETED | Results posted: 2018-01-04